Truist Financial Lowers Perspective Therapeutics (NYSE:CATX) Price Target to $10.00

Perspective Therapeutics (NYSE:CATX) had its price objective cut by research analysts at Truist Financial from $21.00 to $10.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price target would suggest a potential upside of 484.80% from the company’s current price.

Several other equities research analysts have also recently weighed in on CATX. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Perspective Therapeutics in a research note on Monday, March 31st. Scotiabank assumed coverage on Perspective Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price objective for the company. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Royal Bank of Canada dropped their target price on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Thursday, March 27th. Finally, Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $13.22.

Perspective Therapeutics Stock Performance

Shares of NYSE:CATX opened at $1.71 on Monday. The firm has a 50 day moving average of $2.65 and a 200-day moving average of $5.67. Perspective Therapeutics has a 12 month low of $1.62 and a 12 month high of $19.05.

Insider Activity at Perspective Therapeutics

In related news, CEO Johan M. Spoor bought 22,026 shares of the stock in a transaction that occurred on Friday, March 28th. The stock was acquired at an average cost of $2.24 per share, with a total value of $49,338.24. Following the transaction, the chief executive officer now directly owns 59,383 shares in the company, valued at approximately $133,017.92. This trade represents a 58.96 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert F. Williamson III bought 38,145 shares of the business’s stock in a transaction on Monday, March 31st. The shares were bought at an average cost of $2.14 per share, for a total transaction of $81,630.30. Following the completion of the acquisition, the director now directly owns 108,982 shares in the company, valued at approximately $233,221.48. This trade represents a 53.85 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 115,696 shares of company stock worth $256,344 in the last quarter. 3.52% of the stock is owned by insiders.

Institutional Trading of Perspective Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC bought a new stake in shares of Perspective Therapeutics in the 4th quarter valued at $4,132,000. State Street Corp lifted its holdings in Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after buying an additional 1,192,812 shares during the period. Octagon Capital Advisors LP boosted its position in Perspective Therapeutics by 62.1% during the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock valued at $7,352,000 after acquiring an additional 882,528 shares during the last quarter. Affinity Asset Advisors LLC grew its holdings in Perspective Therapeutics by 160.0% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock worth $4,147,000 after acquiring an additional 800,000 shares during the period. Finally, Two Sigma Investments LP bought a new position in shares of Perspective Therapeutics in the 4th quarter worth about $2,075,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.